The company is a high-precision medical industry cluster enterprise in regenerative medicine, specializing in special new technology enterprises. It has been a key project in Beijing for four consecutive years from 2017 to 2020, and is expected to realize the GEM IPO plan in 2024. The independently developed and mass-produced regenerated silicon RegeSi regenerative medicine material has broken the technological monopoly of developed countries in the field of regenerative medicine and filled the gap in regenerative medicine at home and abroad. It has applied for 57 invention patents and 4 international patents, and won the 2018 China Invention Patent Silver Award. Its technology is at the global leading level.
Regenerated silicon RegeSi is listed in the National Key New Materials Catalog, the National Health Commission’s key clinical promotion new technology for wound repair, the National Ministry of Industry and Information Technology’s Intellectual Property Pilot Enterprise, the State Intellectual Property Office’s Innovation Enterprise, the Beijing Key New Materials Catalog, and the Beijing Key Project. This material has the characteristics of promoting orderly growth of cells, promoting cell gene expression, realizing in-situ regeneration of tissues, and quickly growing the same tissues and cells as the original ones. It is widely used in wound repair, chronic wounds, gynecological adhesion prevention, artificial bone, and nerve repair. , in vivo mucosa, bioloaded scaffolds (cartilage repair, targeted drug-loaded scaffolds), medical aesthetics and other more than 10 high-end medical fields are widely used, and will achieve an output value of 100 billion.
National Intellectual Property Pilot Enterprise of the Ministry of Industry and Information Technology, Key Clinical Promotion Project of the National Health Commission, Beijing Specialized and New Enterprise, Beijing Intellectual Property Demonstration Unit, Beijing Natural Fund Support Unit, Beijing High-Precision Industry Project, and National Innovative Medicine Benchmark Top 70 enterprises.
"Ziyuansheng" sterile ointment wound dressing has won the National Health Commission's key clinical promotion technology for wound repair (reviewed by more than 100 medical experts, only Xingfu Yisheng Company). This project has been highly recommended by the Fourth Medical Center of the People's Liberation Army General Hospital and the Academy of Military Medical Sciences of the People's Liberation Army. It is included in the National Trauma Repair Medicine Catalog, Trauma Repair Clinicians' Medication Guide, and National Emergency and Military Supplies. It is promoted nationwide through the National Health New Technology Platform .
In March 2019, it received strategic investment from the State Intellectual Property Office Publishing House (the State Intellectual Property Publishing House is my country’s intellectual property big data management and operation center and is my country’s authoritative patent certification authority) and was registered with the Ministry of Finance. In October 2021, it received investment from the Tianjin Municipal Government Guidance Fund. The paid-in registered capital is 50,535,678 yuan, and 156,908,900 yuan has been invested
The company has 6 medical products that have entered the national medical insurance catalog. Scientific and technological achievements have been transformed into 5 Class III innovative medical devices, 7 Class II innovative medical devices, and 19 medical cosmetology approvals. Special medical beauty products (hair growth, anti-hair loss and hair growth cream, whitening and freckle removal cream), new oral care materials, and daily chemical functional materials are listed in the catalog of the State Food and Drug Administration.
The company has collaborated with 14 scientific research institutions including Peking Union Medical College Hospital, Chinese People's Liberation Army General Hospital, and Peking University School of Stomatology to conduct research on regenerative medicine in cartilage repair, permanent tooth repair, and targeted treatment of cancer tumors. Cooperate with the People's Liberation Army Academy of Military Medical Sciences and the Public Security University in combat casualties and emergency rescue.
In the next 3-5 years, cutting-edge medical products are currently registering 4 innovative medical devices in three categories, which have entered the clinical stage. These products have been approved and will be used in trauma repair, chronic wounds, gynecological adhesion prevention, artificial bone, nerve repair, and in vivo applications. Mucosa, bioloaded scaffolds (cartilage repair, stem cell scaffolds, vascular scaffolds, etc., targeted drug-loaded scaffolds), and other major disease treatments have disruptive significance, and the market space is huge.
Third prize in the 2020 "Maker China" Beijing Small and Medium Enterprises Innovation and Entrepreneurship Competition and "Maker Beijing 2020" Innovation and Entrepreneurship Competition; "Beijing Intellectual Property Demonstration Unit"; honorary title of "Beijing Specialized, Special and New" small and medium-sized enterprises. RegeSi's invention patent for regenerative medicine materials won the "IBIX 2020 British International Invention and Innovation Technology Exhibition Gold Medal"; the company's project won the "Second Prize in the Semi-finals of the 2020 SCIP+ Green Chemistry and Chemical Industry Innovation and Entrepreneurship Competition".
Zhongguancun Pinggu Industrial Demonstration Base, with a 3200-square-meter GMP plant, produces 30 tons of regenerated silicon materials annually. It is a key project of the Beijing Municipality in the high-tech industry of regenerative medicine and has started construction in 2019. The total planned investment is 156 million yuan, and it plans to produce 1000 tons of regenerated silicon materials annually.